|
| |
Immunotherapy with
Bispecific Antibodies
 |
A first effect of treatment with Bispecific
Antibodies will of course be the direct killing of the target cell by
redirecting the cellular toxicity of the effector cell. This is a passive
effect: this action will cease once the reagent is removed from the
body, and it involves effector cells that have no specificity for the
target. |
| Although this already a desirable effect which
many therapies see as an endpoint, it is possible that by using
Bispecific Antibodies, we can achieve more. A correctly stimulated
effector cell will release signal molecules towards other immune cells,
notifying them of a dangerous situation.
The normally immunosuppressive tumor environment can be made
pro-inflammatory by these released signals. If antigen presenting cells
start presenting also tumor antigens, a specific
immune reaction could follow. Since the immune system continues to react
after removal of the triggering reagent, this is called an active
effect. In fact, we can compare it with vaccination, but here we bring
the adjuvant to the antigen. |
|
[Antibodies]
[Immunotherapy] [BsAb]
[Tribody]
| |
|
